Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence
Share
Why It Matters
Aptevo's new leukemia treatment helped ten patients get stronger. This is a good sign that the medicine might work better than older treatments.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.